Recurrent implantation failure: in most cases the limiting factor is the embryo, not the endometrium
A large multicentre analysis of nearly 124,000 patients shows that even after three failed transfers of euploid blastocysts, the probability of live birth does not meaningfully decline. The fourth transfer resulted in a live birth in 40%, the fifth in 53%, with a cumulative live-birth rate of 98% after five euploid transfers.
One of the most important observations is that the live-birth rate after the fourth euploid transfer was comparable to the first transfer, arguing strongly against a cumulative endometrial implantation defect. Instead, implantation success appears primarily determined by embryo competence rather than uterine receptivity alone.
The clinical implication is straightforward: true unexplained recurrent implantation failure (RIF) is probably rare, with an estimated prevalence below 2% once major uterine pathology and chromosomal abnormalities are excluded.
This supports a shift in counselling strategy. Repeated implantation failure is most often related to embryo genetics, which cannot be modified by adjunctive treatment. Even when embryos are euploid, implantation remains influenced by additional embryonic factors such as developmental kinetics, morphology, and genetic variation beyond current testing resolution.
Female age remains the dominant prognostic variable because it determines the probability of obtaining euploid embryos. In practical terms, decisions about whether to continue treatment after several failed transfers depend primarily on the expected likelihood of generating another euploid blastocyst rather than on suspected endometrial pathology.
Importantly, current ESHRE good practice recommendations advise against routine use of investigations such as microbiome profiling, NK-cell testing, cytokine panels, HLA compatibility testing, mitochondrial DNA assessment, or sperm DNA fragmentation testing in this setting. Similarly, interventions such as endometrial scratching, IVIG, intralipid therapy, platelet-rich plasma, LMWH, or empirical immunomodulation should not be offered without evidence of benefit for live-birth outcomes.
For everyday clinical practice, this leads to a clear message: when uterine anatomy is normal and embryo ploidy is confirmed, most repeated failures reflect biological variability in embryo competence rather than a treatable endometrial disorder. Each additional euploid embryo transfer represents a new independent chance of success, not a repetition of the same failed attempt.